KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Common Equity (2016 - 2025)

Historic Common Equity for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $93.1 billion.

  • Pfizer's Common Equity rose 58.13% to $93.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $93.1 billion, marking a year-over-year increase of 58.13%. This contributed to the annual value of $88.5 billion for FY2024, which is 88.59% down from last year.
  • According to the latest figures from Q3 2025, Pfizer's Common Equity is $93.1 billion, which was up 58.13% from $89.0 billion recorded in Q2 2025.
  • Over the past 5 years, Pfizer's Common Equity peaked at $101.2 billion during Q2 2023, and registered a low of $18.7 billion during Q4 2022.
  • Its 5-year average for Common Equity is $82.0 billion, with a median of $89.0 billion in 2025.
  • In the last 5 years, Pfizer's Common Equity crashed by 4808.25% in 2022 and then soared by 42030.83% in 2023.
  • Pfizer's Common Equity (Quarter) stood at $77.5 billion in 2021, then increased by 23.82% to $95.9 billion in 2022, then fell by 6.91% to $89.3 billion in 2023, then fell by 0.89% to $88.5 billion in 2024, then grew by 5.2% to $93.1 billion in 2025.
  • Its Common Equity stands at $93.1 billion for Q3 2025, versus $89.0 billion for Q2 2025 and $90.6 billion for Q1 2025.